VivoSeq
Gastroenterology

Peptic Ulcer

47

Pipeline Programs↗

6

Active Trials↗

22

Companies Involved↗

Peptic ulcer is a moderately active landscape with 47 programs across 22 companies. The most active players are Theracos, Shandong New Time Pharmaceutical Co., LTD, Johnson & Johnson. 16 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Theracos logo

Theracos

1 program

Phase 1S

Shandong New Time Pharmaceutical Co., LTD

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2O

Onconic Therapeutics Inc.

2 programs

Phase 3Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 3A

AVM Biotechnology Inc

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

50

clinical trials

Completed29 · 58%
Unknown status8 · 16%
Recruiting4 · 8%
Terminated4 · 8%
Withdrawn3 · 6%
Not yet recruiting2 · 4%

Clinical Trials

Trial Activity

50 trials

Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
Recruiting·—·N/A·NCT06894992·162 enrolled
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Recruiting·—·Phase 4·NCT05582174·594 enrolled
Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
Recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT06284876·416 enrolled
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
Recruiting·OOnconic Therapeutics Inc.·Phase 3·NCT06439563·364 enrolled
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia
Not yet recruiting·—·Phase 4·NCT07146594·150 enrolled
Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding
Not yet recruiting·SShandong New Time Pharmaceutical Co., LTD·Phase 2·NCT06783257·150 enrolled
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
Completed·Pfizer logoPfizer·Phase 2·NCT00037570·12 enrolled
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00251979·1,312 enrolled
Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding
Completed·LLotung Poh-Ai Hospital·Phase 4·NCT00731601·120 enrolled
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
Completed·Theracos logoTheracos·Phase 1·NCT01155531·40 enrolled
UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD
Completed·NNext Biomedical Co., Ltd.·N/A·NCT02978391·76 enrolled
Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients
Completed·—·Phase 4·NCT02456012·268 enrolled
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
Completed·PPharmaKing·Phase 2·NCT02342470·88 enrolled
Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
Completed·—·Phase 3·NCT01142245·263 enrolled
The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
Completed·NNational Cheng-Kung University Hospital·N/A·NCT02197039·316 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)